Peptide derived from RAGE efficiently improves oocyte development through attenuating oxidative stress in oocytes of mice with polycystic ovary syndrome
Related Experiment Video
Updated: Jul 1, 2025
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
Published on: July 5, 2024
Xiaojing Hou1, Zhonghui Ling1, Yaping Guo1
1Nanjing Women and Children's HealthCare Hospital, Women's Hospital of Nanjing Medical University, Nanjing, China.
Abstract:
Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder in reproductive-aged women that frequently leads to infertility due to poor oocyte quality. In this study, we identified a new active peptide (advanced glycation end products receptors RAGE344-355 ) from PCOS follicular fluid using mass spectrometry. We found that supplementing PCOS-like mouse oocytes with RAGE344-355 attenuated both meiotic defects and oxidative stress levels, ultimately preventing developmental defects. Additionally, our results suggest that RAGE344-355 may interact with eEF1a1 to mitigate oxidative meiotic defects in PCOS-like mouse oocytes. These findings highlight the potential for further clinical development of RAGE344-355 as a potent supplement and therapeutic option for women with PCOS. This research addresses an important clinical problem and offers promising opportunities for improving oocyte quality in PCOS patients.
Insights
Researchers discovered a peptide, RAGE344-355, in PCOS follicular fluid that improves oocyte quality. Supplementing with this peptide reduced defects and oxidative stress in PCOS-like mouse oocytes, offering therapeutic potential for infertility.
Area of Science:
- Endocrinology
- Reproductive Biology
- Molecular Medicine
Background:
- Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting reproductive-aged women.
- PCOS frequently causes infertility due to compromised oocyte quality.
Purpose of the Study:
- To identify novel therapeutic targets for improving oocyte quality in PCOS.
- To investigate the role of specific peptides in PCOS-related infertility.
Main Methods:
- Mass spectrometry was used to identify peptides in PCOS follicular fluid.
- PCOS-like mouse oocytes were supplemented with the identified peptide (RAGE344-355).
- Meiotic defects and oxidative stress levels were assessed.
Main Results:
- A novel active peptide, RAGE344-355, was identified from PCOS follicular fluid.
- Supplementation with RAGE344-355 attenuated meiotic defects and reduced oxidative stress in PCOS-like mouse oocytes.
- RAGE344-355 may interact with eEF1a1 to mitigate oxidative meiotic defects.
Conclusions:
- RAGE344-355 shows potential as a therapeutic agent to improve oocyte quality in women with PCOS.
- This peptide could offer a novel strategy to address infertility associated with PCOS.
- Further clinical development of RAGE344-355 is warranted for PCOS patients.
